Pragmatic Clinical Trial for a More Effective Concise and Less Toxic MDR-TB Treatment Regimen(s) (TB-PRACTECAL)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT02589782

Recruitment Status : Active, not recruiting

First Posted : October 28, 2015

Last Update Posted : May 14, 2021

View this study on Beta.ClinicalTrials.gov

Sponsor:

Collaborators:

London School of Hygiene and Tropical Medicine

Global Alliance for TB Drug Development

University College, London

Drugs for Neglected Diseases

Swiss Tropical & Public Health Institute

eResearch Technology, Inc.

Ministry of Health, Republic of Uzbekistan

World Health Organization

Ministry of Public Health, Republic of Belarus

THINK TB & HIV Investigative Network

University of Liverpool

Wits Health Consortium (Pty) Ltd

Rutgers, The State University of New Jersey

University of California, San Francisco

Information provided by (Responsible Party):

Medecins Sans Frontieres, Netherlands

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Recruitment Status :	Active, not recruiting
Estimated Primary Completion Date :	September 2022
Estimated Study Completion Date :	December 2022

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Berry C, du Cros P, Fielding K, Gajewski S, Kazounis E, McHugh TD, Merle C, Motta I, Moore DAJ, Nyang'wa BT. TB-PRACTECAL: study protocol for a randomised, controlled, open-label, phase II-III trial to evaluate the safety and efficacy of regimens containing bedaquiline and pretomanid for the treatment of adult patients with pulmonary multidrug-resistant tuberculosis. Trials. 2022 Jun 13;23(1):484. doi: 10.1186/s13063-022-06331-8.

To Top